{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-202850","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.098783+00:00","generated_at":"2026-06-12T10:51:03.969955+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ResMed Q4 FY2023 revenue up 23% to $1.12B; EPS $1.56 GAAP, dividend raised 9% to $0.48","bullets":["Revenue $1,122.1M +23% YoY; GAAP diluted EPS $1.56 (+17%), non-GAAP $1.60 (+7%).","Full-year revenue $4,223.0M (+18%); GAAP EPS $6.09 (+15%), non-GAAP $6.44 (+11%).","Gross margin contracted 210 bps to 55.0% (GAAP) and 200 bps to 55.8% (non-GAAP).","Quarterly dividend raised 9% to $0.48/share; record Aug 17, payable Sept 21, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-202850","json":"https://secwatch.observer/filing/0001193125-23-202850.json","markdown":"https://secwatch.observer/filing/0001193125-23-202850.md","text":"https://secwatch.observer/filing/0001193125-23-202850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312523202850/0001193125-23-202850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312523202850/d510491d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:51:03.969955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bc7eb4c7deb3190f83ac87fc23bbb305938ee30","claim":"RESMED INC reported fiscal year ended June 30, 2023 results: revenue $4,223.0, net income $897.6, EPS $6.09.","evidence_excerpt":"per share $ 1.56 $ 1.33 17 Non-GAAP diluted earnings per share (B) $ 1.60 $ 1.49 7 Twelve Months Ended June 30, 2023 June 30, 2022 % Change Constant Currency (A) Revenue $ 4,223.0 $ 3,578.1 18 % 21 % Gross margin 55.8 % 56.6 % (1 ) Non-GAAP gross margin (B) 56.5 % 57.7 % (2 ) Selling, general, and administrative expenses 874.0 737.5 19 22 Research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312523202850/0001193125-23-202850-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended June 30, 2023"},{"label":"Revenue","value":"$4,223.0"},{"label":"Net income","value":"$897.6"},{"label":"EPS","value":"$6.09"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f75aa54e06bde2cb9ce0b7c8ebd01f077c8ea8d2","claim":"RESMED INC reported the quarter ended June 30, 2023 results: revenue $1,122.1, net income $229.7, EPS $1.56.","evidence_excerpt":"Results and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended June 30, 2023 June 30, 2022 % Change Constant Currency (A) Revenue $ 1,122.1 $ 914.7 23 % 23 % Gross margin 55.0 % 57.1 % (4 ) Non-GAAP gross margin (B) 55.8 % 57.8 % (4 ) Selling, general, and administrative expenses 240.7 193.0 25 26 Research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312523202850/0001193125-23-202850-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$1,122.1"},{"label":"Net income","value":"$229.7"},{"label":"EPS","value":"$1.56"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}